11C-匹兹堡化合物B PET在轻链型心脏淀粉样变性患者中的独立预后价值
这项前瞻性队列研究纳入58例连续AL心脏淀粉样变性患者,行11C-PiB PET/CT视觉评估心肌摄取并分为阳性与阴性组,主要终点为1年全因死亡率。心肌11C-PiB摄取阳性是1年死亡率的独立预测因子(校正HR 3.382,95%CI 1.011-11.316,P=0.048),并在3种常用生物标志物基础上提供增量预后价值。
要点
- 58例AL心脏淀粉样变性患者中35例心肌11C-PiB摄取阳性,阳性者1年总生存率更差(81.8% vs 45.5%,P=0.003)。
- 心肌11C-PiB摄取阳性是1年死亡率的独立预测因子(校正HR 3.382,95%CI 1.011-11.316,P=0.048)。
- 在肌钙蛋白I、NT-proBNP、游离轻链差值3种生物标志物基础上加入11C-PiB PET/CT结果,1年死亡率预测性能显著改善。
核心结论
- 11C-PiB PET/CT是AL心脏淀粉样变性患者1年全因死亡率的强独立预测因子,并在3种常用AL淀粉样变性分期生物标志物之外提供增量预后获益。
- 考虑到近年多种淀粉样蛋白靶向分子影像剂的发展,PET/CT是否应纳入AL心脏淀粉样变性患者危险分层尚需进一步研究。
研究设计与样本
- 前瞻性研究,纳入58例连续AL心脏淀粉样变性患者,均行11C-PiB PET/CT。
- 根据PET/CT视觉评估心肌有无11C-PiB摄取,将患者分为2组。
- 主要终点为1年全因死亡率,采用净重分类改善和综合判别改善分析11C-PiB PET/CT的独立预后价值。
主要发现
- 58例入组患者中35例心肌11C-PiB摄取阳性。
- 心肌11C-PiB PET摄取阳性者1年总生存率较无摄取者更差(81.8% vs 45.5%,P=0.003,log-rank检验)。
- 多因素分析中,心肌11C-PiB摄取阳性是1年死亡率的独立预测因子(校正风险比3.382,95%CI 1.011-11.316,P=0.048)。
- 在肌钙蛋白I≥0.1 ng/mL、NT-proBNP≥1,800 pg/mL、游离轻链差值≥180 mg/L三个亚组中,Kaplan-Meier曲线均显示心肌11C-PiB摄取阳性者预后较阴性者更差。
- 将11C-PiB PET/CT结果加入3种生物标志物后,1年死亡率预测性能显著改善:净重分类改善分别为肌钙蛋白I 0.861、NT-proBNP 0.914、游离轻链差值0.987;综合判别改善分别为0.200、0.156、0.108。
关键数值与推荐
- 心肌11C-PiB摄取阳性定义为PET/CT视觉评估显示心肌有11C-PiB摄取。
- 3种常用AL淀粉样变性分期生物标志物及阈值:肌钙蛋白I至少0.1 ng/mL、NT-proBNP至少1,800 pg/mL、游离轻链差值至少180 mg/L。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出,PET/CT是否应纳入AL心脏淀粉样变性患者危险分层尚需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
11C-Pittsburgh compound B (PiB) PET/CT visualizes the amount of myocardial amyloid deposit and can be used to prognosticate patients with amyloid light-chain (AL) cardiac amyloidosis (CA). However, whether 11C-PiB PET/CT has any independent additional prognostic value beyond the commonly used biomarkers remains unknown. Methods: This prospective study was on a cohort of 58 consecutive patients with AL CA who underwent 11C-PiB PET/CT. The patients were stratified into 2 groups on the basis of a visual assessment of whether there was myocardial 11C-PiB uptake on PET/CT. The primary endpoint was 1-y overall mortality. The independent prognostic utility of 11C-PiB PET/CT was analyzed using net reclassification improvement and integrated discrimination improvement. Results: Among the 58 patients enrolled, 35 were positive for myocardial 11C-PiB uptake on PET/CT. Patients with myocardial 11C-PiB PET uptake had a worse 1-y overall survival rate than those without (81.8% vs. 45.5%, P = 0.003 by log-rank test). In the multivariate analysis, positivity for myocardial 11C-PiB uptake on PET/CT was an independent predictor of 1-y mortality (adjusted hazard ratio, 3.382; 95% CI, 1.011-11.316; P = 0.048). In analysis of 3 subgroups of patients-those with a troponin I level of at least 0.1 ng/mL, those with an N-terminal pro-B-type natriuretic peptide (NT-proBNP) level of at least 1,800 pg/mL, and those with a difference of at least 180 mg/L between free light chains (the 3 commonly used biomarkers and their thresholds for staging in AL amyloidosis)-Kaplan-Meier curves showed for all 3 subgroups that patients positive for myocardial 11C-PiB uptake on PET/CT had a worse prognosis than those who were negative. Additionally, when the results of 11C-PiB PET/CT were added to these 3 biomarkers, the performance of 1-y mortality prediction significantly improved by net reclassification improvement (troponin I, 0.861; NT-proBNP, 0.914; difference between free light chains, 0.987) and by integrated discrimination improvement (0.200, 0.156, and 0.108, respectively). Conclusion:11C-PiB PET/CT is a strong independent predictor of 1-y overall mortality and provides incremental prognostic benefits beyond the 3 commonly used biomarkers of AL amyloidosis staging. Considering the recent development of numerous amyloid-targeting molecular imaging agents, further investigations are warranted on whether PET/CT should be included in risk stratification for patients with AL CA.
引用
- Choi YJ, Koh Y, Lee HJ, et al. Independent Prognostic Utility of 11C-Pittsburgh Compound B PET in Patients with Light-Chain Cardiac Amyloidosis. J Nucl Med. 2021. PMID: 34916248. doi:10.2967/jnumed.121.263033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。